EGFR and neoplasm: Tumor volume at the end of the study (day 21) showed a highly significant growth inhibition with the EGFR BiTE® vs. MEC14 control BiTE® for implants with EGFR-positive cells or mixed EGFR-positive and -negative tumor cells, but not for implants containing only EGFR-negative tumor cells (Fig 4B).